Inozyme Pharma Inc. (INZY)
1.19
-0.01 (-0.83%)
At close: Mar 03, 2025, 12:30 PM
Inozyme Pharma Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY01 |
| Net Income | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M | n/a |
| Depreciation & Amortization | 833K | 744K | 674K | 217K | 83K | 26K | n/a |
| Stock-Based Compensation | 7.04M | 7.67M | 7.16M | 2.31M | 301K | 444K | n/a |
| Other Working Capital | -1.7M | 1.86M | 760K | -2.21M | 684K | 629K | n/a |
| Other Non-Cash Items | -4.29M | -1.13M | 378K | 18.04M | -71K | -4.37M | n/a |
| Deferred Income Tax | n/a | n/a | 170K | n/a | n/a | n/a | n/a |
| Change in Working Capital | -3.08M | 2.01M | 85K | -111K | 601K | 1.43M | n/a |
| Operating Cash Flow | -70.67M | -57.76M | -48.15M | -35.97M | -18.81M | -9.44M | n/a |
| Capital Expenditures | -298K | -410K | -397K | -568K | -139K | -259K | n/a |
| Acquisitions | n/a | 4.99K | -43.19K | 116.61K | 8.25K | n/a | n/a |
| Purchase of Investments | -269.33M | -151.99M | -121.97M | -177.92M | -24.66M | -13.57M | n/a |
| Sales Maturities Of Investments | 215.98M | 147M | 165.16M | 61.31M | 16.41M | 22.83M | n/a |
| Other Investing Acitivies | n/a | -4.99K | 43.19K | -116.61K | -8.25K | 9.27M | n/a |
| Investing Cash Flow | -53.65M | -5.4M | 42.8M | -117.18M | -8.39M | 9.01M | n/a |
| Debt Repayment | 40M | 4.05M | n/a | n/a | n/a | n/a | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 322K | 12.6M | 609K | 33.84M | 22.97M | 31.95M | n/a |
| Financial Cash Flow | 125.97M | 72.79M | 609K | 149.81M | 22.97M | 31.95M | n/a |
| Net Cash Flow | 1.63M | 9.6M | -4.72M | -3.34M | -4.23M | 31.51M | n/a |
| Free Cash Flow | -70.97M | -58.17M | -48.55M | -36.54M | -18.95M | -9.7M | n/a |